Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Figure 6

Progression-free survival by fold increase in plasma VEGF-A. Group A (n = 10): Patients that had lower than average fold increase of plasma VEGF-A at the end of cycle 2, Group B (n-14): Patients that had higher than average fold increase of plasma VEGF-A at the end of cycle 2. Median PFS = 134 vs. 367 days, p = 0.010 by log-rank test, HR = 0.2 (95% CI = 0.059–0.68).

Back to article page